Novartis India Ltd
NSE:NOVARTIND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Novartis India Ltd
Intangible Assets
Novartis India Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novartis India Ltd
NSE:NOVARTIND
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Intangible Assets
₹100.9B
|
CAGR 3-Years
47%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Intangible Assets
₹19.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
26%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Intangible Assets
₹136.8B
|
CAGR 3-Years
32%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Intangible Assets
₹25.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Intangible Assets
₹40.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Novartis India Ltd
Glance View
Novartis India Ltd. engages in developing and marketing transformative treatments for people in areas of medical need. The company is headquartered in Mumbai, Maharashtra and currently employs 81 full-time employees. The firm focuses on over three divisions, including pharmaceuticals, eye care and generic medicines. In India, its pharmaceutical business is focused on bone and pain, calcium portfolio, gynecology and neurosciences, and the generics business is focused on gynecology, anti-tuberculosis (TB) and anti-infectives. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolism, immunology and dermatology, ophthalmology, neuroscience and respiratory. The company develops gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The company is developing a chimeric antigen receptor (CAR)-T platform for various investigational CAR-T therapies in its pipeline. The firm has presence in various locations in India, including Delhi, Bengaluru, Kolkata, Chennai and Lucknow.
